Compare · AMIX vs RMD
AMIX vs RMD
Side-by-side comparison of Autonomix Medical Inc. (AMIX) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMIX and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $32.03B, about 7619.8x AMIX ($4.2M).
- Over the past year, AMIX is down 84.1% and RMD is down 6.1% - RMD leads by 78.0 points.
- Both names hit the wire about 2 times in the past 4 weeks.
- RMD has more recent analyst coverage (25 ratings vs 0 for AMIX).
- Company
- Autonomix Medical Inc.
- ResMed Inc.
- Price
- $0.36+1.14%
- $219.82+0.11%
- Market cap
- $4.2M
- $32.03B
- 1M return
- -11.12%
- -2.86%
- 1Y return
- -84.09%
- -6.09%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 2
- 2
- Recent ratings
- 0
- 25
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest AMIX
- Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026
- Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026
- SEC Form S-8 filed by Autonomix Medical Inc.
- Autonomix Medical to Present at LSI USA '26
- Autonomix Medical Selected for Best Innovation Competition at CRT 2026
- Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis
- Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation
- Autonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation
- SEC Form 10-Q filed by Autonomix Medical Inc.
- Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting
Latest RMD
- Analyst initiated coverage on ResMed
- SEC Form 4 filed by Farrell Michael J.
- SEC Form 4 filed by Sandercock Brett
- SEC Form 4 filed by Farrell Peter C
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,252,902 worth of ResMed Common Stock (4,991 units at $251.03) (SEC Form 4)
- Director Farrell Peter C sold $520,440 worth of ResMed Common Stock (2,000 units at $260.22), decreasing direct ownership by 3% to 62,773 units (SEC Form 4)
- SEC Form 144 filed by ResMed Inc.